SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-057651
Filing Date
2021-11-18
Accepted
2021-11-18 17:00:40
Documents
14
Period of Report
2021-11-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K SHARE REPURCHASE PLAN ljpc-8k_20211117.htm   iXBRL 8-K 34264
2 EX-99 ljpc-ex99_6.htm EX-99 5817
3 GRAPHIC gbqnxzztk1dn000001.jpg GRAPHIC 8059
  Complete submission text file 0001564590-21-057651.txt   181363

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20211117.xsd EX-101.SCH 5737
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20211117_lab.xml EX-101.LAB 19335
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20211117_pre.xml EX-101.PRE 11525
7 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-8k_20211117_htm.xml XML 3551
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 211425157
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences